Aescap Life Sciences
Aescap Life Sciences is a biotech fund that invests in publicly traded biotech companies. It invests in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics and/or medical devices. Aescap Life Sciences has around 210 million euros under management and has an annualized net performance of 7% over its five years of existence. Entry into and exit from this biotech fund is possible twice per month.
The biotech market is a large and fast-growing market. The substantial growth of the biotech market, also called life sciences market, is driven by an ageing population and an increased demand for ‘Western’ medicine in the emerging markets. After 30 years of development groundbreaking technologies such as RNA, gene and cell therapies come to the market which often allow for more effective and safer medicines. These factors together are driving demand for improved and cost-effective medicine, diagnostics and medical devices. Since there more than 1.000 public biotech companies it is difficult to select those that will be beat their competitors in the future. With over 30 years of experience investing in the life sciences market Aescap Life Sciences provide investors to invest into the future winners of this industry. An investment in the fund will not only generate a good return on investment, it also enables the development of better treatments for diseases with a high unmet medical need such as ALS, Alzheimer’s, Arthritis, Cancer, MS, Obesity, Parkinson’s and many others.
The fund has a focused portfolio, investing in approximately 20 companies. Within this focus it will ensure that the portfolio is diversified over many different diseases and geographic areas. The fund’s objective is to make an annual net return (after deduction of all fees) of 20% over the mid-term (4-5 years). The name Aescap is derived from Aesculapius, the Roman god of Medicine, and “Capital”.
Aescap Life Sciences was founded by portfolio manager Patrick Krol in March 2016. He developed a highly disciplined investment strategy based on his own experience investing in public biotech companies over more than 30 years, during which he went through several stock market cycles. He believes the fund’s buy/sell discipline and risk management is key to its success. Also, he does not shy away from being an activist investor where necessary. Mr. Krol’s strategy has resulted in an outstanding performance that has granted Aescap Life Sciences a 5-star Morningstar rating (the highest rating available) and has generated an exceptional annualized return to investors in the fund, see the ‘Performance’ page.
Aescap Life Sciences is managed by Privium Fund Management B.V. (Privium) as Alternative Investment Fund Manager of the fund. The Fund Manager is responsible for the management of the fund in accordance with the provisions of the Fund Documents and applicable laws. Privium Fund Management B.V. is authorized and regulated by the Dutch Authority for the Financial Markets (www.afm.nl) as an Alternative Investment Fund Manager (AIFM) as referred to in article 2:65 (a). Both Privium and the fund are registered in the Register of AFM. Privium is an Asset Manager with offices in Amsterdam, London and Hong Kong and focuses on alternative investments. As a group, Privium is managing over USD 2.3 billion. For additional information on the Fund Manager please visit Privium’s website at: www.priviumfund.com.